SNSE

Sensei Biotherapeutics, Inc.

SNSE · CIK 1829802 · Annual (10-K) · Last 4 years

Financial Trends

Revenue
20212024
Net Income−$30M
20212024
Operating CF−$25M
20212024
Free Cash Flow−$25M
20212024

Income Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕
Revenue————
Cost of Revenue————
Gross Profit————
R&D Expense————
SG&A Expense————
Operating Income$-0.0B$-0.0B$-0.1B$-0.0B
Net Income$-0.0B$-0.0B$-0.0B$-0.0B
EPS (Basic)$-1.20$-1.22$-1.58—
EPS (Diluted)$-1.20$-1.22$-1.58—

Balance Sheet

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕
Total Assets$0.0B$0.1B$0.1B$0.2B
Current Assets$0.0B$0.1B$0.1B$0.1B
Cash & Equivalents$0.0B$0.0B$0.0B$0.0B
Total Liabilities$0.0B$0.0B$0.0B$0.0B
Current Liabilities$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$0.0B$0.1B$0.1B$0.1B

Cash Flow Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕
Operating Cash Flow$-0.0B$-0.0B$-0.0B$-0.0B
Investing Cash Flow$0.0B$0.0B$0.0B$-0.1B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$-0.0B$-0.0B$-0.0B$0.2B
← Companies